Cas12

CRISPR gene editing can lead to integration of mitochondrial DNA (mtDNA) fragments into the nuclear genome, raising potential safety concerns in...

Dosing Underway in World’s First in Vivo CRISPR...

CMN Clinical

Aug. 28, 2024

YolTech Therapeutics announced last week that the first two patients have been dosed in a Phase 1 trial of YOLT-203, an in vivo CRISPR-based...

HuidaGene Receives Special Designation for...

CMN Clinical

Feb. 14, 2024

HuidaGene Therapeutics recently announced that the FDA has granted Orphan Drug Designation to its CRISPR-based therapeutic candidate, HG302. The...

Cas12a chRDNA - A Novel Approach to Gene-Editing...

Mar. 6, 2023

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

Catch up on CRISPR COVID-19 Diagnostics

Aug. 10, 2021

As the COVID-19 pandemic continues to evolve with fluctuating restrictions worldwide, mass vaccine rollouts and the emergence of new variants, it's...

CRISPR Diagnostics Update: Cas12a-based SARS-CoV-2...

May. 19, 2021

This week’s update looks at a CRISPR-Cas12a-based detection method, developed in China as a confirmatory tool to aid SARS-CoV-2 diagnosis.